Ardelyx CEO to speak at Wedbush nephrology conference

Ardelyx Inc. (NASDAQ: ARDX) announced that President and CEO Mike Raab will participate in a fireside chat at the Wedbush Rewind ASN 2025 Conference on November 10, 2025, from 11:30 a.m. to 12:00 p.m. ET.

The biopharmaceutical company stated the event will be accessible via public webcast through the Events and Presentations section of the Ardelyx website. A replay will remain available on the company's website for 30 days following the conference.

Ardelyx has two commercial products approved in the United States: IBSRELA and XPHOZAH, both containing the active ingredient tenapanor. The company is developing RDX10531, described as a next-generation NHE3 inhibitor.

The company has international commercialization agreements for tenapanor. Kyowa Kirin markets PHOZEVEL for hyperphosphatemia in Japan, while Fosun Pharma received approval for a New Drug Application for tenapanor for hyperphosphatemia in China. Knight Therapeutics commercializes IBSRELA in Canada.

You May Also Be Interested In

• Fermi names Lee McIntire as CEO, effective August 11
• Cable One names Heather McCallion as chief operating officer
• JP 3E Holdings adds three directors with life sciences backgrounds